Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Skyrizi. Always confirm against the full prescribing information.
100 interactions
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Risankizumab.
Level 2 evidence
AstraZeneca COVID-19 Vaccine
The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Risankizumab.
The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Risankizumab.
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Risankizumab.
Level 2 evidence
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Risankizumab.
Level 1 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Aducanumab is combined with Risankizumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Alirocumab is combined with Risankizumab.
Level 2 evidence
Allogeneic processed thymus tissue
The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Risankizumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Amivantamab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Risankizumab is combined with Ansuvimab.
Level 2 evidence
Asfotase alfa
The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Risankizumab.
Level 2 evidence
Enter your NPI to unlock 67 major interactions for Skyrizi
Skyrizi (Risankizumab-Rzaa) has 378 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Skyrizi (Risankizumab-Rzaa) has 221 major, 38 moderate, and 119 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Skyrizi. Always confirm against the full prescribing information.